Forte Biosciences stock edges higher after argenx takeover closes

Published on 09/01/2026 at 21:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Forte Biosciences stock is trading slightly higher after the argenx acquisition closed on August 27, 2026, leaving the small biotech effectively integrated into its larger European peer while its Nasdaq listing and options presence adjust to the new ownership structure.

FBRX, US34960P1012, Illustration mit AI erstellt.

Forte Biosciences stock (ISIN US34960P1012) most recently changed hands at 76.99 USD on Nasdaq as of August 26, 2026, with data compiled on September 1, 2026 indicating a modest daily gain of 0.03 % and a market capitalization of about 108 million USD according to a technical snapshot from Zonebourse.

Acquisition by argenx reshapes Forte story

The key corporate event for Forte Biosciences in 2026 is its takeover by argenx SE, which was finalized on August 27, 2026, as highlighted in an insider-transactions overview from Zonebourse.

The same overview notes that Forte Biosciences shares, at 76.99 USD as of the August 26, 2026 Nasdaq close, were up 0.09 % year to date and had delivered a striking 182.32 % performance over the last 12 months for shareholders who held through the acquisition period, underlining how strongly the market repriced the company ahead of the argenx deal.

Trading levels and options delisting

Price data collected on September 1, 2026 shows that Forte Biosciences stock was quoted at 76.99 USD on Nasdaq and 77.00 USD on CBOE at the last recorded close, with the same snapshot assigning the company a market capitalization of 108 million USD, based on figures presented in the Zonebourse quote and chart sections.

In parallel with the equity consolidation under argenx, the US options markets are adapting: an alert from the MIAX Emerald options platform dated September 1, 2026 states that Forte Biosciences, Inc. (ticker FBRX) will be delisted from the MIAX Options, MIAX Pearl Options, MIAX Emerald Options and MIAX Sapphire Options exchanges, signaling that listed derivatives on the stock are being wound down following completion of the takeover, as detailed in the MIAX Emerald options alerts page.

Go deeper

More on Forte Biosciences stock and filings

Background articles, regulatory filings and further corporate news related to Forte Biosciences can be found in the dedicated ISIN overview and on the company investor relations page.

More news on US34960P1012 Investor Relations

Lead dermatology program under larger parent

Before the acquisition, Forte Biosciences focused on developing treatments in dermatology and immunology, including experimental therapies in inflammatory skin disease; with argenx having completed the takeover on August 27, 2026, these programs are now expected to be advanced within a larger late stage autoimmune and immunology pipeline.

Stock level and investor takeaway

As of the last completed Nasdaq session on August 26, 2026, Forte Biosciences stock at 76.99 USD sat firmly above levels seen one year earlier, with the referenced 182.32 % 12 month performance highlighting the extent to which investors who entered before the takeover announcement have benefited from the revaluation tied to argenx ownership, according to the compiled Zonebourse performance figures.